INTRODUCTION
============

Major depressive disorder (MDD), a common mental disorder worldwide, is characterized by persistent depression and loss of interest. In developed countries, its lifetime prevalence is around 15% \[[@b1-pi-2020-0045],[@b2-pi-2020-0045]\]. MDD is associated not only with poor productivity but also with decreased quality of life and increased mortality \[[@b3-pi-2020-0045]\]. Deficits include cognitive, motor, perception, and communication impairments \[[@b4-pi-2020-0045]\]. Several recent reviews have reported impairments in cognitive function, including attention and executive function \[[@b5-pi-2020-0045]-[@b9-pi-2020-0045]\]. These cognitive impairments are related to social function, psychiatric symptoms, and prognosis. For example, with regard to neurocognitive function, impairments in visual memory, perceptual reasoning, and motor skills have been found to predict functional outcome six months later \[[@b10-pi-2020-0045]\], while impairments in executive function have a critical influence on daily life activities \[[@b11-pi-2020-0045]\] and are clearly related to suicidal ideation \[[@b12-pi-2020-0045]\]. However, the exact changes in brain functionality that cause these impairments in cognitive function in MDD remain to be elucidated.

Recent research efforts have been actively invested in elucidating the biological basis of mental illnesses. For this aim in particular, novel diagnostic imaging techniques and refined analytic methods have been developed. In MDD research, abnormalities in brain morphology and function of the cerebral neocortex have been reported, particularly in the frontotemporal cortex \[[@b13-pi-2020-0045]-[@b15-pi-2020-0045]\]. Additionally, recent neurological advances have furthered understanding of the functional differentiation of the frontotemporal cortex, while gradually revealing the mapping of cognitive functions \[[@b16-pi-2020-0045]-[@b19-pi-2020-0045]\].

Alongside functional neuroimaging techniques such as single photon emission computerized tomography (SPECT), positron emission tomography (PET), and functional magnetic resonance imaging (fMRI), near-infrared spectroscopy (NIRS) has revealed itself to be a novel, useful technique in the field of neuropsychiatric disorders for measuring brain function \[[@b20-pi-2020-0045]-[@b24-pi-2020-0045]\]. NIRS exploits the fact that near-infrared light (range, 700-1,000 nm) is partially absorbed by hemoglobin, thus allowing for the detection of intratissue hemoglobin concentration changes and the examination of intratissue blood volume and oxygen metabolism. NIRS data primarily reflects intracapillary hemoglobin and enables measurement of its oxygenated (oxy-Hb) and deoxygenated (deoxy-Hb) forms, as well as its total amount. Oxy-Hb is commonly used as the most sensitive parameter. By measuring hemoglobin concentration changes between a baseline period and a period of relative activation, NIRS allows for the examination of brain activation. Compared to other functional neuroimaging techniques, NIRS can simply and noninvasively measure spatiotemporal changes in brain function while the subject remains in a natural posture \[[@b25-pi-2020-0045],[@b26-pi-2020-0045]\].

Several studies have used NIRS to study MDD and have reported an overall lower activation reactivity during verbal fluency tasks (VFT) in bilateral prefrontal and temporal surface regions in patients with MDD compared to healthy controls, suggesting that reduced activation in these regions is a biomarker of MDD \[[@b27-pi-2020-0045]-[@b32-pi-2020-0045]\]. Further, many studies have used NIRS with VFT as the activation task and have reported that functional changes in frontotemporal cortex activation correlates with MDD clinical characteristics. One such study, for example, showed evidence of reduced prefrontal activation even when clinical symptoms were in remission \[[@b33-pi-2020-0045]\]. Another reported reduced right temporal cortex activation in patients with severe negative automatic thoughts \[[@b34-pi-2020-0045]\], while another revealed lower frontotemporal activation in patients with MDD with melancholic features than in those without melancholic features \[[@b35-pi-2020-0045]\]. The same group also reported decreased left precentral gyrus activation in suicide attempters compared to non-attempters \[[@b36-pi-2020-0045]\]. Nonetheless, several aspects of the relationship between the various clinical features of MDD, including impairment in cognitive function and the functional differentiation of frontotemporal cortex activation, remain to be elucidated. Considering that improvement in cognitive function is extremely important in treating patients with MDD, investigating this relationship will contribute to the creation of objective test methods based on biological indicators of cognitive impairment, as well as to the development of effective intervention methods for MDD.

The aim of this study was to shed light on the relationship between functional differentiation of the frontotemporal cortex and cognitive functions. To this end, we extensively examined frontotemporal cortical function in hospitalized patients with MDD using multi-channel NIRS. We hypothesize that functional activity of the frontotemporal cortex in patients with MDD is correlated to specific cognitive functions and that this relationship is discernable by NIRS.

METHODS
=======

Participants
------------

Participants included 18 inpatients with MDD (MDD group) and 22 healthy individuals (control group) who were matched for age, sex, years of education, and estimated intelligence quotient (IQ). All participants had an estimated IQ of 85 or above and were native speakers of Japanese. Participants in the MDD group included individuals who were inpatients at the Arima Hospital, who, during their hospitalization, were diagnosed with MDD by an experienced psychiatrist according to the guidelines of the Diagnostic and Statistical Manual of Mental Disorders 5 \[[@b37-pi-2020-0045]\]. Participants were excluded if they displayed any of the following: MDD with psychotic features, history of head trauma with loss of consciousness, current or past neurological disease, current or past endocrine disease, history of treatment by electroconvulsive therapy, alcohol or substance abuse or dependence, diabetes, hypertension, heart disease, liver disease, cerebrovascular disease, and left-handedness \[[@b38-pi-2020-0045]\]. Eighteen patients (12 men, 6 women; mean age 44.2±8.7) on psychotropic medication at the time of testing fulfilled criteria for inclusion in the study. Among them, 17 were taking antidepressants, 7 were taking antipsychotics, 15 were taking anxiolytics, and 4 were taking mood stabilizers. Antipsychotics were being used to alleviate the symptoms of insomnia and to reinforce the antidepressant therapy. Among the four subjects prescribed mood stabilizers, two had been using lithium carbonate to reinforce the antidepressant therapy. The subjects also included some patients who, though diagnosed with MDD, were suspected of having bipolar disorder on admission. Therefore, although drug use was being minimized on admission, one patient was prescribed sodium valproate and another lamotrigine. The daily dosage of all antidepressants, antipsychotics, and anxiolytics was converted to the equivalent dose of imipramine, chlorpromazine, and diazepam, respectively \[[@b39-pi-2020-0045]\]. All patients were in a depressive state, scoring 10 points or above, on the 17-item Hamilton Rating Scale for Depression (HAM-D) \[[@b40-pi-2020-0045]\].

We chose to use inpatients for this study since they are more likely to be able to receive active medical care than those receiving outpatient treatment. Therefore, early understanding of the condition on hospitalization allows for the administration of more appropriate treatment on a priority basis.

Healthy individuals who were appropriately age- and sexmatched to the MDD group participated as controls in the present study. Inclusion criteria were the same as those for the MDD group, but also included no current or past history of psychiatric consultation, no history of psychiatric illness in second-degree relatives, and no psychotropic medication taken at the time of testing. Twenty-two healthy controls (11 men, 11 women; mean age 42.0±10.9) fulfilled these criteria.

Demographic and clinical characteristics of all participants are summarized in [Table 1](#t1-pi-2020-0045){ref-type="table"}. As evaluated by chi-squared tests, Student's t-tests, and Mann-Whitney U tests, we did not observe any significant differences between groups for sex, age, or years of education. All tests, including NIRS, were conducted on the same day.

This study was approved by the ethical review board of the Arima Hospital (IRB approval number: 2015-4) and the Kobe University Graduate School of Health Sciences (IRB approval number: 404-1). All participants received a full briefing of the goal and details of the study prior to participation. All participants provided written consent. The research was conducted in compliance with guidelines set forth by the World Medical Association Declaration of Helsinki.

Clinical assessment
-------------------

Depression symptoms were assessed using the 17-item HAM-D \[[@b40-pi-2020-0045]\]. Estimated IQ was calculated using the Japanese version of the National Adult Reading Test \[[@b41-pi-2020-0045]\].

Cognitive assessment
--------------------

Cognitive function was evaluated using the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS-J) \[[@b42-pi-2020-0045],[@b43-pi-2020-0045]\]. Though the BACS-J is a test of neurocognition for schizophrenia, it has also been used for MDD \[[@b44-pi-2020-0045]-[@b46-pi-2020-0045]\]. It is composed of six subscales: verbal memory, working memory, motor speed, verbal fluency, attention and speed of information processing, and executive function. A higher score reflects higher functioning across all scales. We used raw scores for all statistical analyses performed in this study.

VFT and NIRS measurements
-------------------------

Hemoglobin concentration changes were measured during VFT trials while participants sat in a chair with their eyes open. The VFT was performed according to the protocol laid out by Takizawa et al. \[[@b28-pi-2020-0045]\]. The protocol used was similar to that used in the neuroimaging-aided differential diagnosis of depressive states. The imaging time was 30 s for acquiring the pre-task baseline, 60 s for the VFT, and 70 s for acquiring the post-task baseline. In both baseline conditions (pre- and posttask), the five vowels of the Japanese language "a, i, u, e, o" were repeated. The VFT condition was divided into three 20-s periods; in the first, second, and third period, the subject was asked to state as many words as possible beginning with the sounds "a," "ki," and "ha," respectively. Task performance was calculated according to the total number of words answered correctly ([Figure 1](#f1-pi-2020-0045){ref-type="fig"}).

Relative oxy-Hb/deoxy-Hb changes were measured based on the modified Beer-Lambert Law \[[@b47-pi-2020-0045]\] with a 52-channel NIRS device (ETG-4000 Optical Topography System; Hitachi Medical Co., Tokyo, Japan) using two wavelengths of near-infrared light, 695 and 830 nm. This method allows for the calculation of signals reflecting Hb concentration changes and their conversion to arbitrary units (mM·mm). The device beams near-infrared light onto the cranium and measures the relative change in the amount of light that is reflected back to the scalp after diffusion through cranial tissues. The distance between each pair of source-detector probes was set at 3 cm, and the area measured between the pair of probes was defined as a "channel." Since the NIRS device measures the mean amount of blood within 2--3 cm from the scalp, it can measure changes in cerebral cortical activity \[[@b48-pi-2020-0045],[@b49-pi-2020-0045]\]. NIRS probes were fixed in place with 3×11 thermoplastic shells. The bottom row of measurement probes was placed above Fp1 and Fp2, according to the international 10--20 method ([Figure 2A](#f2-pi-2020-0045){ref-type="fig"}). We utilized 33 probes which consisted of 17 light emitters and 16 detectors. Therefore, the probe consisted of 52 channels ([Figure 2B](#f2-pi-2020-0045){ref-type="fig"}). The spatial information of the respective channels was estimated using data from the Functional Brain Science Laboratory at the Jichi Medical University, Japan \[[@b50-pi-2020-0045],[@b51-pi-2020-0045]\]. We hypothesized that NIRS channels can measure hemoglobin concentration in areas corresponding to the bilateral frontal, temporal, and parietal cortices according to LONI Probabilistic Brain Atlas (LPBA40) \[[@b52-pi-2020-0045]\] ([Figure 2C](#f2-pi-2020-0045){ref-type="fig"}--[E](#f2-pi-2020-0045){ref-type="fig"}).

The temporal resolution of the NIRS device was set to 0.1 s. The obtained data were analyzed using the 'integral mode', using a 10-s pre-task baseline interval immediately before the VFT, and a 5-s post-task baseline interval, beginning 50 s after the end of the VFT. We created a first-order correction baseline using the least-squares method, based on these two baseline intervals, and calculated the amount of change from baseline. To eliminate high frequency noise, such as heartbeats or small body movements, we set the moving average method to 5 s. Using previously adopted computer algorithms \[[@b53-pi-2020-0045]\], we excluded channel data with excessive artifacts, which explains the different number of participants for each channel.

Simultaneous NIRS and fMRI studies have strongly correlated cerebral blood flow to oxy-Hb rather than to deoxy-Hb \[[@b54-pi-2020-0045]\]. Therefore, we focused on oxy-Hb data.

Statistical analysis
--------------------

We confirmed the normal distribution of demographic data (age, education, estimated IQ), HAM-D score, cognitive function (scores from the six subscales for BACS-J), and task performance using the Shapiro-Wilk test, after which we performed a chi-squared test, Student's t-test, or Mann-Whitney U test, as appropriate, to assess differences between the MDD and control groups.

A student's t-test was performed to compare differences in mean VFT-induced oxy-Hb changes for each channel between the two groups. Since there were 52 channels to be analyzed, t-tests were performed 52 times. The use of many channels in the analysis incurred a high likelihood of introducing a type II error should a Bonferroni correction be used for multiple comparisons. Therefore, a false discovery rate (FDR)-based procedure was adopted to correct for multiple comparisons. To ensure that the false positive rate did not exceed 5% on average, we set a q value establishing a maximum FDR of 0.05 \[[@b55-pi-2020-0045]\]. To assess correlations between mean oxy-Hb changes and demographic and clinical variables (age, years of education, estimated IQ, HAM-D score, illness duration, number of depressive episodes, duration of depressive episodes, task performance, imipramine dose, chlorpromazine dose, and diazepam dose) in the MDD group, we conducted Pearson's or Spearman's correlation analysis, as appropriate, and applied an FDR correction.

Additionally, to assess correlation between mean oxy-Hb changes and cognitive function (scores from the six subscales for BACS-J) in the MDD group, we conducted a Pearson's or Spearman's correlation analysis, as appropriate, and applied an FDR correction.

Finally, a correlation analysis was carried out with a control group to assess whether the correlation detected in the aforementioned correlation analysis was reproducible. Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 24.0 (IBM Corp., Armonk, NY, USA) in Windows.

RESULTS
=======

Demographic data, depression severity, and task performance
-----------------------------------------------------------

Demographic and clinical data are shown in [Table 1](#t1-pi-2020-0045){ref-type="table"}. The HAM-D score was significantly higher in the MDD than in the control group (U=0.000, p\<0.001). We did not detect a significant difference in the number of generated words in the VFT (U=195.0, p=0.935) ([Table 1](#t1-pi-2020-0045){ref-type="table"}).

Cognitive functions
-------------------

We found significant differences between the control and MDD groups, with the MDD group performing more poorly on the following subscales scores of the BACS-J: motor speed (U=123.5, p=0.042), attention and speed of information processing (t=-3.060, p=0.004), and executive function (U=127.0, p=0.049) ([Table 1](#t1-pi-2020-0045){ref-type="table"}).

Mean oxy-Hb changes during the VFT
----------------------------------

Mean VFT-induced oxy-Hb changes were significantly lower in patients with MDD than in healthy individuals for 15 channels located in the bilateral prefrontal and temporal surface regions (ch15, ch22, ch26-27, ch30, ch32-33, ch38, ch40-42, ch44, ch48, ch51-52; FDR-corrected p=0.0006 to 0.0137) ([Figure 3](#f3-pi-2020-0045){ref-type="fig"}).

Correlation analyses
--------------------

In the MDD group, the number of depressive episodes was significantly negatively correlated with the mean VFT-induced oxy-Hb changes in two channels covering the left superior temporal gyrus (ch31, 42), left supramarginal gyrus (ch31), left angular gyrus (ch31), and left middle temporal gyrus (ch42) (ch31, ch42; *rho*=-0.745 to -0.603, FDR-corrected p=0.0010 to 0.0014). After multiple comparisons correction with FDR, there was no significant correlation between the mean oxy-Hb changes and other demographic or clinical variables (age, years of education, estimated IQ, HAM-D score, illness duration, duration of depressive episodes, task performance, imipramine dose, chlorpromazine dose, and diazepam dose) ([Supplementary Table 1](#SD1-pi-2020-0045){ref-type="supplementary-material"} in the online-only Data Supplement).

In the MDD group, the BACS-J motor speed score was significantly positively correlated with mean oxy-Hb changes in one channel covering the left superior temporal gyrus and the left middle temporal gyrus (ch52; *rho*=0.904, FDR-corrected p\<0.0001) ([Figure 4](#f4-pi-2020-0045){ref-type="fig"}). However, no significant correlation was found between the other five BACS-J subscale scores (verbal memory, working memory, verbal fluency, attention and speed of information processing, and executive function) and mean oxy-Hb changes after multiple comparisons correction with FDR ([Supplementary Table 2](#SD2-pi-2020-0045){ref-type="supplementary-material"} in the online-only Data Supplement).

For healthy participants, we failed to find any significant correlation between the BACS-J motor speed and the mean oxy-Hb changes after multiple comparisons correction with FDR for any channel (*rho*=-0.591 to 0.253, p=0.0047 to 1.0000).

DISCUSSION
==========

Cognitive function
------------------

This study demonstrated that patients with MDD perform more poorly in motor speed, attention and speed of information processing, and executive function than healthy controls matched for age, sex, and years of education. These three neurocognitive dysfunctions were also observed in a previous study using BACS-J \[[@b46-pi-2020-0045]\].

Mean oxy-Hb changes during the VFT
----------------------------------

Although we did not detect differences in the number of generated words in the VFT between the MDD and control groups, the mean VFT-induced oxy-Hb changes in the entire bilateral prefrontal and temporal surface regions were lower in the MDD than the control group. This result is consistent with previous reports \[[@b27-pi-2020-0045],[@b29-pi-2020-0045]-[@b32-pi-2020-0045]\] and suggests that reduced mean oxy-Hb changes in the bilateral prefrontal and temporal surface regions may constitute a biomarker for MDD.

Correlation analyses
--------------------

We found that the number of depressive episodes was significantly negatively correlated with the mean VFT-induced oxy-Hb changes in the left superior temporal gyrus, left supramarginal gyrus, left angular gyrus, and left middle temporal gyrus. It has been reported that the length of past depressive episodes negatively influences memory performance \[[@b56-pi-2020-0045]\]; accordingly, more depressive episodes may also reduce activation of the left temporal region and subparietal district.

We found that motor speed scores positively correlated with the mean VFT-induced oxy-Hb changes in the left superior temporal gyrus and left middle temporal gyrus. These findings indicated that the more the motor speed is limited, the further these changes are reduced. In this study, a token motor task was used to measure the motor speed. In this task, the subjects are given 100 plastic tokens and instructed to place them two at a time into a container as quickly as possible \[[@b42-pi-2020-0045]\]. The temporal lobe accounts for 17% of the cerebral cortex and includes areas with auditory, olfactory, vestibular, visual, and linguistic functions \[[@b57-pi-2020-0045]\]. This is consistent with the findings of previous studies showing that the temporal area is activated during a VFT \[[@b58-pi-2020-0045]\] and is involved in visuomotor coordination \[[@b59-pi-2020-0045]\]. Additionally, in a study on MDD evaluation using SPECT, researchers found a negative correlation between psychomotor retardation severity, measured by the Unified Parkinson's disease rating scale (UPDRS), and frontal and temporal perfusion \[[@b60-pi-2020-0045]\]. Moreover, studies using NIRS have reported a negative correlation between psychomotor retardation score, measured by the HAM-D, and mean VFT-induced oxy-Hb changes in the frontal and bilateral temporal regions in patients with MDD \[[@b30-pi-2020-0045]\], or in the frontal and left temporal regions in those with MDD with non-melancholic features \[[@b35-pi-2020-0045]\]. Our study primarily demonstrated a relationship between the left temporal region and motor speed, consistent with these previous studies. However, our study provides further significant quantitative and objective support to this relationship, since it quantitively assessed motor speed using the BACS-J. These previous studies, in contrast, had assessed psychomotor function based solely on interviews and clinical observation using the UPDRS and HAM-D.

Since we did not observe a relationship between motor speed and temporal region activation in healthy controls, we consider that the presence of such correlation is specific to patients with MDD. However, it remains unclear whether these results are due to abnormal neural correlates or compensatory mechanisms. Nonetheless, in MDD, the relationship between temporal region activation and motor speed likely demonstrates its essential role in maintaining motor speed. Overall, our results further the understanding of MDD pathophysiology.

Limitations
-----------

This study has a few limitations. First, we utilized multiple comparison corrections to avoid Type I errors, but due to the relatively small sample size, we cannot rule out the possibility of Type II errors. Second, although depressive symptoms primarily ranged in severity from mild to moderate, since all participants were inpatients, it remains unclear whether the results are reproducible in an outpatient cohort. Additionally, inpatients undergo a number of therapeutic changes over the course of their treatment, making it difficult to properly assess baseline cerebral metabolism. Third, not all medications were stringently regulated. Although the discriminating MDD, bipolar disorder, and schizophrenia were similar between a small group not administered with the drug and that administered with the drug \[[@b28-pi-2020-0045]\]. Further evidence is needed to elucidate the effect of drugs on cerebral metabolism.

Conclusions
-----------

We extensively investigated frontotemporal cortical function in patients with MDD using multi-channel NIRS. As expected, we discovered that functional differentiation of the frontotemporal cortex correlates with cognitive function. We suggest that reductions in VFT-induced mean oxy-Hb changes in the left superior temporal gyrus and the left middle temporal gyrus may be used as a biomarker for poor motor speed in MDD. We propose that NIRS can not only assist in the differential diagnosis of MDD but can also be used for assessing poor motor speed.
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![Design of the verbal fluency task.](pi-2020-0045f1){#f1-pi-2020-0045}

![Measurement points for the 52 NIRS channels. A: Probes with 3×11 thermoplastic shells were placed on the scalp of the subject over the bilateral frontotemporal regions. B: Placement of the 17 emitters and 16 detectors. The 52 measurement areas are labeled ch1--ch52, from the right posterior to the left anterior region. C--E: Anatomical positions corresponding to each channel.](pi-2020-0045f2){#f2-pi-2020-0045}

![Comparison of mean oxy-Hb changes during the VFT. A: Brain regions shown in red correspond to NIRS channels with significantly lower levels of mean oxy-Hb changes in patients with MDD than in healthy controls (FDR-corrected p\<0.05), and those shown in blue are not significant. B: Grand-averaged waveforms of the mean oxy-Hb changes in patients with MDD and healthy controls. MDD: major depressive disorder, oxy-Hb: oxygenated hemoglobin, VFT: verbal fluency task, NIRS: near-infrared spectroscopy, FDR: false discovery rate.](pi-2020-0045f3){#f3-pi-2020-0045}

![Relationship between mean oxy-Hb changes and motor speed scores in patients with MDD. A: Significant correlation is shown as a red-colored channel (FDR-corrected p\<0.05), and non-significant correlations are shown as blue-colored channels. B: Scatter diagram showing the relationship between motor speed scores and mean oxy-Hb changes in ch52. MDD: major depressive disorder, FDR: false discovery rate.](pi-2020-0045f4){#f4-pi-2020-0045}

###### 

Demographic and clinical characteristics of patients with MDD and healthy controls

                                Patients with MDD (N=18)                                                            Healthy controls (N=22)                         Analysis                                                                                 
  ----------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------- ----------- ------------------- -------------------------------------------------------- ------------------------------------------------------
  Demographic characteristics                                                                                                                                                                                                                                
                                Age (years)                                                                         44.2±8.9                                        42.0±11.2   t ~(df=38)~=0.665   0.510                                                    
                                Sex (female/male)                                                                   6/12                                            11/11       χ^2^=1.13           0.289                                                    
                                Education (years)                                                                   15.0±2.5                                        15.2±1.5    U=195.0             0.929                                                    
                                Estimated IQ                                                                        108.1±7.9                                       106.3±6.8   t ~(df=38)~=0.773   0.444                                                    
                                Duration of illness (months)                                                        70.3±98.6                                                                                                                                
                                Depressive episodes (number)                                                        1.7±1.3                                                                                                                                  
                                Duration of current episode (weeks)                                                 56.1±58.7                                                                                                                                
  Clinical variables                                                                                                                                                                                                                                         
                                HAM-D                                                                               15.8±4.9                                        1.7±1.4     U=0.000             \<0.001^[\*](#tfn1-pi-2020-0045){ref-type="table-fn"}^   
                                Task performance                                                                    15.9±5.6                                        15.4±4.6    U=195.0             0.935                                                    
                                BACS-J                                                                                                                                                                                                                       
                                                                                                                    Verbal memory                                   40.1±10.6   44.3±7.5            t ~(df=29.71)~=-1.436                                    0.162
                                                                                                                    Working memory                                  21.1±3.5    21.3±4.0            U=190.5                                                  0.837
                                                                                                                    Motor Speed                                     79.9±15.4   88.9±7.6            U=123.5                                                  0.042^[\*](#tfn1-pi-2020-0045){ref-type="table-fn"}^
                                                                                                                    Verbal fluency                                  47.8±12.4   46.1±10.0           t ~(df=38)~=0.480                                        0.634
                                                                                                                    Attention and speed of information processing   58.9±8.3    66.4±7.1            t ~(df=38)~=-3.060                                       0.004^[\*](#tfn1-pi-2020-0045){ref-type="table-fn"}^
                                                                                                                    Executive function                              17.3±3.1    19.0±1.8            U=127.0                                                  0.049^[\*](#tfn1-pi-2020-0045){ref-type="table-fn"}^
                                Imipramine equivalent dose (mg)^[†](#tfn2-pi-2020-0045){ref-type="table-fn"}^       165.4±129.9                                                                                                                              
                                Chlorpromazine equivalent dose (mg)^[‡](#tfn3-pi-2020-0045){ref-type="table-fn"}^   23.3±35.9                                                                                                                                
                                Diazepam equivalent dose (mg)^[§](#tfn4-pi-2020-0045){ref-type="table-fn"}^         15.4±25.1                                                                                                                                

Data are presented as mean±standard deviation.

Significant p values,

antidepressant dosages were evaluated using the imipramine equivalent dosage,

antipsychotic dosages were evaluated using the chlorpromazine equivalent dosage,

anxiolytic dosages were evaluated using the diazepam equivalent dosage.

MDD: major depressive disorder, IQ: intelligence quotient, HAM-D: 17-item Hamilton Rating Scale for Depression, BACS-J: Japanese version of the Brief Assessment of Cognition in Schizophrenia
